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Obesity has reached epidemic proportions in the United States, currently ranking 
second among causes of preventable deaths.  Our research group has shown in cultures of 
differentiated human adipocytes that 30 uM trans-10, cis-12 Conjugated Linoleic Acid 
(CLA) increases IL-6 and IL-8 secretion into the media and lowers mRNA levels of 
peroxisome proliferator-activated receptor gamma (PPARγ).  Human adipose tissue 
explants were incubated with either vehicle or 30 uM trans-10, cis-12 CLA for 8, 24, or 
72 h.  Trans-10, cis-12 CLA treatment increased IL-6 and IL-8 secretion into the media 
(p < 0.05).  Trans-10, cis-12 CLA treatment also increased the mRNA levels of IL-6 and 
IL-8 (p < 0.05) while having no significant effect on PPARγ or PPARγ targets.  These 
data demonstrate for the first time that CLA induces IL-6 and IL-8 gene expression and 
protein secretion in cultures of human subcutaneous adipose tissue explants.
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CHAPTER I 
 
 
INTRODUCTION 
 
 
 
Significance 
 
Obesity is currently the second leading cause of preventable deaths in the U.S. (Mokdad 
et al. 2004).  The estimated annual medical spending attributed to obesity is $92.6 billion, 
or approximately 9.1% of U.S. Health expenditures (Finkelstein et al. 2003).  
Traditionally, low-fat diets are recommended to prevent obesity.  However, specific 
isomers of the polyunsaturated fatty acid conjugated linoleic acid (CLA) reduces body fat 
in animals (Azain et al. 2000, Ryder et al. 2001, Park et al. 1999, deDeckere et al. 1999, 
Ostrowska et al. 2003) and in some humans (Gaullier et al. 2004).  However, the 
antiobesity actions of CLA in humans is controversial because recent studies have shown 
mixed results.  Some CLA studies report no significant decrease in adiposity (Malpuech-
Brugere et al. 2004) while others report a significant decrease (Gaullier et al. 2004).  
What is needed is research demonstrating the extent to which trans-10, cis-12 CLA is 
operative in human adipose tissue.  Our research group demonstrated that treatment of 
cultures of newly differentiated human adipocytes for 7-21 d with 30 uM trans-10, cis-12 
CLA decreased the triglyceride (TG) content compared to cultures treated with 30 uM 
cis-9, trans-11 CLA or vehicle (Brown et al. 2004).  Our group has also shown that trans-
10, cis-12 CLA induces the release of proinflammatory cytokines, (e.g., IL-6 and IL-8),
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that precede a decrease in adipogenic gene expression and delipidation (Brown et al. 
2004).  However, it is not known whether CLA affects cytokines and adipogenic gene 
expression in intact adipose tissue as it does in cultures of newly differentiated 
adipocytes.  Therefore, the hypothesis was that CLA increases cytokine secretion and 
suppresses adipogenic gene expression as it does in cultures of adipocytes.  To test this 
hypothesis, the following specific aim was pursued:  Determine the extent that trans-10, 
cis-12 CLA increases IL-6 and IL-8 gene expression and protein secretion and 
decreases peroxisome proliferator activated receptor (PPAR)γ2 and its downstream 
targets in human adipose tissue explants.   
This research is important because it will provide a better understanding of how CLA 
decreases adiposity.  A better understanding of these effects will facilitate the 
development of dietary strategies to control the development of obesity, a major cause of 
preventable morbidity and mortality in the U.S. 
 
Biological Effects of Conjugated Linoleic Acid (CLA) 
Dr. Michael Pariza’s group at the University of Wisconsin Madison was the first to 
discover CLA, a geometric and positional isomer of linoleic acid, while studying 
carcinogens in grilled beef (Ha et al. 1987).  CLA exists primarily as two naturally 
occurring isomers, cis-9, trans-11 and trans-10, cis-12 CLA.  Animal studies with crude 
mixtures of CLA isomers have demonstrated beneficial biological effects on cancer 
(Palombo et al. 2002, Yang et al. 2002, Cho et al. 2003), diabetes (Houseknecht et al. 
1998, Belury et al. 2003), atherosclerosis (Kritchevsky et al. 2002, Toomey et al. 2003), 
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immune function (Yu et al. 2002, Akahoshi et al. 2002, Yang et al. 2003), and body 
composition (Park et al. 1999a, Park et al. 1999b, Park et al. 2001, Ryder et al. 2001, 
Terpstra et al. 2002, Ostrowska et al. 2003, Wargent et al. 2005).  Animals fed an equal 
mixture (~ 1%, w/w) of cis-9, trans-11 CLA and trans-10, cis-12 CLA had decreased 
body fat, increased lean body mass, and reduced excess weight gain.  However, because 
the mixtures used in these studies contained two or more CLA isomers, it is difficult to 
pinpoint which isomer is responsible for the decreasing adiposity.  Current studies 
demonstrate that trans-10, cis-12 CLA is the isomer primarily responsible for reduced 
adiposity in vivo (reviewed by House et al. 2005).  For example, trans-10, cis-12 CLA 
decreased adiposity in pigs (Tischendorf et al. 2002, Wiegand et al. 2002, Ostrowska et 
al. 2003), hamsters (de Deckere et al. 1999, Gavino et al. 2000, Navarro et al. 2003), and 
rodents (Tsuboyama-Kasaoka et al. 2000, Ryder et al. 2001, Terpstra et al. 2002, 
Yamasaki et al. 2003).  In vitro evidence also supports the notion that trans-10, cis-12 
CLA is the isomer responsible for suppressing preadipocyte differentiation and 
promoting mature adipocyte delipidation.  For example, trans-10, cis-12 CLA treatment 
decreased TG content in 3T3-L1 preadipocytes, inhibiting their differentiation into 
mature adipocytes (Brodie et al. 1999, Evans et al. 2001, Kang et al. 2003, Granlund et 
al. 2005).  3T3-L1 adipocytes treated with trans-10, cis-12 CLA altered fatty acid 
metabolism and reduced TG content (Park et al. 1999a, Choi et al. 2000, Granlund et al. 
2005).  In addition, our group has shown that 30 uM trans-10, cis-12 CLA decreased TG 
content in primary cultures of human differentiating preadipocytes (Brown et al. 2003) 
and in cultures containing newly differentiated adipocytes (Brown et al. 2004). 
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Adipocyte Biology 
The process of adipocyte differentiation commonly referred to as adipogenesis, is 
regulated by numerous transcription factors including PPAR and CCAAT/enhancer-
binding proteins (C/EBP).  The activity of these transcription factors, and to a lesser 
extent the expression of these genes, can be altered by a variety of hormones, growth 
factors, and nutrients.  These alterations can either promote or inhibit adipocyte 
differentiation, thereby inducing a number of metabolic changes in adipose tissue. 
 One of the main transcription factors involved in the regulation of adipogenesis is 
PPARγ.  PPARγ is one member of the PPAR family of nuclear hormone receptors whose 
activity is modulated by ligand binding and heterodimerization with retinoid X receptor 
(RXR).  Of the three members of the PPAR family, PPARγ is the most important 
regulator of adipogenesis in adipose tissue.  This is supported by the following research:  
1) activation of PPARγ2, an isoform resulting from alternative splicing of the PPARγ 
gene, by high affinity, synthetic ligands such as thiazolidinediones (TZD) upregulates 
genes involved in adipocyte differentiation (Sewter et al. 2002); 2) peroxisome 
proliferator response elements (PPRE) have been found in the promoter sequences of 
genes abundantly expressed during adipogenesis, including adipocyte fatty acid binding 
protein (aP2) and lipoprotein lipase (LPL) (Lemberger et al. 1996); 3) PPARγ2 knockout 
animals had fewer mature adipocytes in adipose tissue (He et al. 2003, Imai et al. 2004); 
and 4) nonprogenitor cells ectopically expressing PPARγ2 and grown in adipogenic 
conditions expressed markers of adipocyte differentiation (Rosen et al. 1999). 
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 The critical role of PPARγ2 in adipogenesis and maintenance of the adipocyte 
phenotype led researchers to study effectors such as growth factors and nutrients that 
decrease or prevent these molecular events driven by PPARγ.  In addition, they were 
interested in the impact these changes would have on gene expression and adipocyte 
metabolism (e.g., glucose and fatty acid uptake, lipogenesis, β-oxidation, lipolysis).  
Several groups have reported that cytokines such as tumor necrosis factor alpha (TNFα) 
and IL-6 and specific fatty acids such as octanoate suppress PPARγ2 gene expression and 
activity in vivo and/or in vitro.  For example, 24 h TNFα (0.2 nmol/L) treatment 
suppressed PPARγ gene expression in 3T3-L1 adipocytes.  PPARγ target genes 
regulating insulin-stimulated glucose uptake (e.g., GLUT4) and fatty acid uptake (e.g., 
LPL) were also downregulated by TNFα (Ruan et al. 2002).  Xing et al. (1997) reported 
that treating 3T3-L1 preadipocytes with 25 ng/mL TNFα inhibited differentiation by 
reducing PPARγ mRNA levels.  They also demonstrated that TNFα decreased PPARγ 
mRNA, protein, and DNA-binding activity in 3T3-L1 adipocytes compared to controls.  
Recently, Rotter et al. (2003) reported that 20 ng/mL TNFα or IL-6 treatment reduced 
mRNA levels for PPARγ and its downstream target GLUT4 in 3T3-L1 adipocytes, 
although TNFα decreased these parameters more rapidly than IL-6.  3T3-L1 adipocytes 
treated with 100-200 ng/mL IL-6 failed to maintain their adipocyte phenotype due to 
decreased PPARγ protein levels and reductions in the mRNA levels aP2, fatty acid 
synthase (FAS), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  In addition, 
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de novo lipogenesis and insulin-stimulated glucose transport were suppressed by IL-6 
consistent with decreased expression of GLUT4 (Lagathu et al. 2003). 
 Concentrations of 1-3 mmol/L of octanoate, a medium-chain fatty acid (MCFA), 
attenuated PPARγ gene and protein expression in 3T3-L1 adipocytes (Farmer et al. 
2002).  Additionally, octanoate-treated adipocytes had higher ratios of the inactive 
phosphorylated PPARγ protein than the nonphosphorylated active protein, which 
suggests octanoate works to inhibit adipogenesis by suppressing PPARγ gene expression 
and activation (Farmer et al. 2002).  Another study reported decreased mRNA levels of 
PPARγ in rats fed MCFAs (Han et al. 2003).  Taken together, these studies with 
cytokines and/or medium-chain fatty acids suggest suppression of PPARγ2 gene 
expression and activity are associated with the following effects in differentiating 
adipocytes:  1) decreased lipid accretion during differentiation (Xing et al. 1997, Farmer 
et al. 2002, Han et al. 2003); 2) decreased expression of PPARγ downstream adipogenic 
target genes regulating adipocyte differentiation (Lagathu et al. 2003, Farmer et al. 2002, 
Han et al. 2003; and 3) decreased insulin-stimulated glucose uptake and de novo 
lipogenesis (Lagathu et al. 2003).  In addition, treatment with cytokines or MCFA 
decreased PPARγ gene expression in mature adipocytes and adipose tissue resulting in:  
1) reduced expression of adipocyte marker genes (Ruan et al. 2002, Rotter et al. 2003, 
Lagathu et al. 2003, Han et al. 2003); 2) delipidation of adipocytes via decreased insulin-
stimulated glucose uptake (Rotter et al. 2003) and de novo lipogenesis (Han et al. 2003); 
and 3) reduced LPL activity resulting in decreased fatty acid uptake in adipose tissue 
(Han et al. 2003). 
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 Consistent with these data, our group has shown that trans-10, cis-12 CLA, but 
not cis-9, trans-11 CLA, suppressed the gene expression of PPARγ2 and its downstream 
targets in cultures of human preadipocytes (Brown et al. 2003) and adipocytes (Brown et 
al. 2004).  The trans-10, cis-12 CLA-dependent downregulation of PPARγ2 and its target 
genes resulted in reduced glucose and fatty acid uptake, incorporation into lipid, and 
oxidation in differentiating preadipocytes (Brown et al. 2003) and mature adipocytes 
(Brown et al. 2004).   
 Collectively, these studies have increased our understanding of the molecular and 
metabolic alterations induced by PPARγ modulators in differentiating and mature 
adipocytes.  While they provide evidence of PPARγ modulators, such as CLA as 
potential anti-obesity agents, these benefits may be outweighed by their potential to 
promote insulin resistance (DeLany et al. 1999, Tsuboyama-Kasaoka et al. 2000, Roche 
et al. 2002) and/or lipodystrophy (Tsuboyama-Kasaoka et al. 2000, Clement et al. 2002, 
Takahashi et al. 2003). 
 
Cytokines 
Following the discovery of leptin [reviewed in (Flier et al. 1998)], a hormone secreted by 
adipose tissue, scientists began to appreciate that adipose tissue functions as an endocrine 
organ.  A number of other adipose-derived secretory molecules, such as hormones and 
cytokines,  have demonstrated pleiotrophic roles in adipocyte differentiation and 
metabolism. For example, the cytokine TNFα inhibits differentiation (Xing et al. 1997, 
Ruan et al. 2002) and increases lipolysis (Gasic et al. 1999, Zhang et al. 2002).  The 
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cytokine IL-6 decreases adipogenesis (Lagathu et al. 2003), insulin-stimulated glucose 
uptake, de novo lipogenesis, and increases lipolysis (Path et al. 2001, Rotter et al. 2003, 
Lagathu et al. 2003) in cultures of mature adipocytes.  Further research identified and 
characterized cytokine cell membrane receptors in murine and human cell types, 
including adipocytes.  Cytokine receptors are signal transduction receptors, which 
become activated when a ligand (i.e., cytokine) binds to the receptor.  Upon activation, a 
signal is transmitted within the cell that causes a number of responses such as changes in 
gene expression and metabolism.  This suggests a role for cytokines in molecular 
signaling mechanisms, or cross talk that enables adipocytes to communicate with other 
adipocytes or with non-adipocytes, impacting their gene expression and metabolism as 
shown in Figure 1.  Recent evidence obtained from murine 3T3-L1 cells and human 
adipose tissue demonstrate that a significant portion of cytokines are synthesized and 
secreted from the non-adipocytes, or supporting stromal vascular (SV) cells compared to 
the adipocytes (Weisberg et al. 2003, Fain et al. 2003, Harkins et al. 2004).  In addition, 
research with recombinant cytokines (Souza et al. 2003) and cytokine neutralization 
antibodies (Hotamisligil et al. 1999, Brown et al. 2004) have verified that cytokines 
activate intracellular signaling in multiple cell types.  These signaling pathways induce 
changes in downstream gene expression and metabolism in adipocytes (Brown et al. 
2004).  Figure 1 summarizes some of the metabolic processes in adipocytes, such as 
insulin-stimulated glucose and fatty acid uptake, lipolysis, and lipogenesis, that can be 
mediated by cytokines.  Taken together, these data provide strong evidence of cross talk 
in adipose tissue where cytokines, secreted primarily from non-adipocytes, bind to 
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Figure 1.  The pleiotropic functions of molecules secreted from adipose tissue.  Potential 
functions of cytokines, hormones, and free fatty acids secreted from adipose tissue are 
illustrated (adapted from Morrison et al. 2000).
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membrane-bound receptors on adipocytes, transducing signals that alter adipocyte gene 
expression and metabolism.  
Cytokines and Inflammation 
Recent studies have shown that secretion of proinflammatory cytokines increases with 
adiposity (Xu et al. 2003, Weisberg et al. 2003).  Proinflammatory cytokines 
hypersecreted during obesity are associated with insulin resistance and type 2 diabetes 
(Pickup et al. 1997, Bastard et al. 2000, Kern et al. 2001, Pradhan et al. 2001, Muller et 
al. 2002).  Human studies have demonstrated higher plasma levels of IL-6 (Bastard et al. 
2000, Kern et al. 2001) and TNFα (Hotamisligil et al. 1995, Moller et al. 2000) are 
associated with insulin resistance and type 2 diabetes.  As a result of these and other 
related findings, many research groups are focusing on cytokines and their involvement 
in the molecular mechanisms linking obesity, inflammation, and the development of 
insulin resistance, type 2 diabetes, and hyperlipidemia.  Through their respective receptor 
systems, the cytokines TNFα and/or IL-6 can activate inflammatory signaling pathways 
such as nuclear factor-κB (NFκB), Jun NH2-terminal kinase (JNK), and extracellular 
signal-regulated kinases 1 and 2 (ERK1/2) (Ruan et al. 2003, Minden et al. 1994, Zhang 
et al. 2002).   
 It is now generally accepted that the inflammatory response observed in 
obesity is initiated in adipose tissue (Xu et al. 2003, Weisberg et al. 2003).  However, the 
mechanisms triggering the initial inflammatory response in adipose tissue remain unclear 
as do the predominant cellular source of cytokines.  It is well-established that adipose 
tissue is compromised of a number of different cell types, among them macrophages, 
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preadipocytes, and reticuloendothelial cells (Weisberg et al. 2003, Xu et al. 2003, 
Abderrahim-Ferkoune et al. 2004).  More importantly, each of these cell types has been 
shown to secrete proinflammatory cytokines (Fain et al. 2003, Harkins et al. 2004, 
Weisberg et al. 2003).  Wellen et al. 2003 proposed one of the best theoretical models to 
date explaining the mechanism by which the inflammatory response is triggered and 
maintained in adipose tissue of the obese.  According to the model, cross-talk (e.g, 
molecular signaling) between adipocytes and non-adipocytes (i.e., macrophages, 
preadipocytes, and reticuloendothelial cells) is mediated by cytokines that can activate 
inflammatory pathways in adipocytes.  The activation of inflammatory pathways 
modulates adipocyte glucose and lipid metabolism, ultimately causing delipidation and 
insulin resistance in adipose tissue. 
 Recent evidence supports the concept that cytokines (e.g., TNFα, IL-6, and 
IL-8) can activate inflammatory pathways (e.g,, NFκB, JNK, and ERK1/2) modulating 
adipocyte glucose and lipid metabolism (Hirosumi et al. 2002, Ruan et al. 2002, Ryden et 
al. 2002, Zhang et al. 2002, Ruan et al. 2003, Souza et al. 2003, Engelman et al. 2005).  
In addition, studies suggest that cytokine-induced activation of these inflammatory 
pathways can suppress adipocyte differentiation (Chae et al. 2003, Souza et al. 2003, 
Suzawa et al. 2003) and promote the delipidation of differentiating and mature adipocytes 
(Zhang et al. 2002, Souza et al. 2003), leading to the development of insulin resistance 
and type 2 diabetes. 
 Recent studies with differentiating adipocytes provide evidence that known 
activators of ERK1/2 and JNK, transcription factors belonging to the mitogen-activated 
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protein kinase (MAPK) signaling family, can phosphorylate PPARγ, thereby reducing its 
transcriptional activity (Hu et al. 1996, Adams et al. 1997, Camp et al. 1997).  Following 
growth factor treatment, adipocytes expressing PPARγ mutated at consensus MAP kinase 
phosphorylation sites have greater PPARγ transcriptional activity, due to less ERK-
mediated inhibitory phosphorylation of PPARγ, while adipocytes expressing wild-type 
PPARγ have greater ERK-mediated phosphorylation of PPARγ, resulting in a decrease in 
PPARγ transcriptional activity (Hu et al. 1996).  Importantly, 3T3-L1 cells treated with 
growth factors and ectopically expressing wild-type PPARγ have a lower degree of 
adipocyte differentiation, indicated by decreased gene expression of PPARγ downstream 
targets regulating glucose and lipid metabolism (e.g., aP2 and adipsin) and reduced TG 
stores.  This evidence suggests cytokines can activate inflammatory pathways in 
differentiating adipocytes that mediate the phosphorylation of PPARγ.  Phosphorylation 
of PPARγ decreases its activity resulting in a concomitant downregulation of adipogenic 
genes regulating adipocyte glucose and lipid metabolism during the differentiation 
process. 
 In mature adipocytes, cytokines can also activate the ERK pathway and 
induce delipidation by stimulating lipolysis.  Souza et al. (2003) demonstrated that 10 
ng/mL TNFα increased ERK activity in 3T3-L1 adipocytes.  To determine whether the 
ERK activation was necessary for TNFα-stimulated lipolysis, 3T3-L1 cells were 
pretreated with PD98059, an upstream inhibitor of mitogen-activated protein 
kinase/extracellular signal-regulated kinase kinase (MEK) blocking ERK activation.  
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Pretreatment with PD98059 attenuated TNFα-induced lipolysis.  Souza et al. (2003) 
proposed that TNFα (10 ng/mL) activates ERK which then phosphorylates PPARγ 
reducing its transcriptional activity.  They also demonstrated a decrease in the protein 
expression of perilipin, a PPARγ target gene.  Therefore, they attribute TNFα-induced 
lipolysis in 3T3-L1 adipocytes to decreased PPARγ activity and a concomitant decrease 
in the protein expression of perilipin.  In summary, the data of Souza et al. 2003 suggest 
that TNFα activates ERK in mature adipocytes, decreasing PPARγ activity and perilipin 
protein expression.  The decrease in perilipin induces lipolysis in 3T3-L1 adipocytes.  
This finding is supported by data demonstrating that overexpression of perilipin blocks 
TNFα-induced lipolysis (Souza et al. 1998). 
 In addition to suppressing adipocyte differentiation and stimulating lipolysis 
in mature adipocytes, recent evidence has shown that cytokines can activate 
inflammatory pathways in adipocytes resulting in impaired insulin signaling.  Mature 
3T3-L1 adipocytes treated for 24 h with TNFα activate NFκB leading to decreased 
expression of a number of genes including GLUT4 and proteins [(e.g., GLUT4, insulin 
receptor substrate 1 (IRS-1), and protein kinase B (AKT)] critical to insulin signaling and 
glucose uptake (Ruan et al. 2002).  3T3-L1 adipocytes treated with TNFα and stably 
expressing a non-degradable (i.e., non-phosphorylatable) form of the inhibitor of NFκB 
(i.e, IκB-α) had higher levels of IκB-α than wild-type adipocytes, further implicating 
TNFα’s role in inducing NFκB.  Ruan et al. (2003) also reported a potential mechanism 
by which TNFα-induced NFκB activation inhibits the transcriptional activity of PPARγ.  
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Using a reporter gene assay in HeLa cells, they demonstrated that a member of the NFκB 
family, p65, decreases basal and PPARγ ligand-induced transcriptional activity.  They 
also showed that the decrease in PPARγ activity is not due to inhibitory binding of p65 to 
NFκB response elements (NFκB RE) in the promoter region of PPARγ responsive 
reporter genes.  This would suggest p65 binds directly to PPARγ to reduce its activity or 
that it associates with known co-activators of PPARγ.  Decreased PPARγ activity could 
potentially explain the suppression of proteins regulating insulin signaling and glucose 
uptake in adipocytes.  Therefore, these data from 3T3-L1 adipocytes support the 
following concepts:  1) TNFα activates NFκB inflammatory signaling in mature 
adipocytes; 2) NFκB activation decreases PPARγ activity, resulting in decreased 
expression of PPARγ-regulated proteins critical to insulin signaling and glucose uptake; 
3) decreased expression of insulin signaling proteins can reduce glucose uptake in 
adipocytes; and 4) reduced glucose uptake decreases the TG content of mature adipocytes 
by reducing the amount of substrates available for de novo TG sysnthesis. 
 These data examining the effects of proinflammatory cytokines on adipocyte 
glucose and lipid metabolism taken together with data reported by Fain et al. 2003, 
Weisberg et al. 2003, and Harkins et al. 2004 demonstrating the predominant cellular 
source (i.e., SV cells vs. adipocytes) of cytokines in adipose tissue support the theoretical 
model proposed by Wellen et al. 2003.  Figure 2 summarizes the following sequence of 
molecular and metabolic events involved in the cross-talk between adipocytes and non- 
adipocytes:  1) Macrophages recruited to adipose tissue by unknown signal(s) infiltrate 
adipose tissue and reside there; 2) non-adipocytes residing in adipose tissue
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Figure 2.  Cross-talk mechanisms between insulin receptor signaling and inflammatory 
pathways.  As the number and size of adipocytes in adipose tissue increases with obesity, 
adipocytes secrete low levels of the cytokine, TNFα.  TNFα acts in a paracrine fashion, 
stimulating the non-adipocyte cells in adipose tissue [(i.e, stromal vascular cells 
(SVCs))], such as preadipocytes and endothelial cells, to produce and secrete monocyte 
chemoattractant protein-1 (MCP-1) (Xu et al. 2003).  Recent evidence suggests that 
MCP-1 can act as a signal, attracting macrophages to adipose tissue where they take up 
residence (Xu et al. 2003).  In addition, increased secretion of leptin and/or decreased 
secretion of adiponectin by adipocytes has been shown to stimulate transport of 
macrophages to adipose tissue (Sierra-Honigmann et al. 1998).  Evidence suggests 
residing macrophages and SVCs are the predominant source of secreted cytokines (e.g., 
IL-6, IL-1β, IL-8, and TNFα) in adipose tissue (Fain et al. 2003, Xu et al. 2003, Weisberg 
et al. 2003, Harkins et al. 2004).  These cytokines can act in an autocrine/paracrine 
fashion to activate inflammatory signaling pathways in adipocytes, leading to insulin 
resistance (adapted from Wellen et al. 2003)
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(macrophages, preadipocytes, and reticuloendothelial cells) and adipocytes secrete 
cytokines (e.g., TNFα, IL-6, and IL-8) which can act in an autocrine/paracrine fashion to 
activate inflammatory signaling pathways (e.g. JAK/STAT, MAPK, NF-κB) in 
adipocytes; 3) cytokine-mediated activation of inflammatory pathways modulates 
adipocyte glucose and lipid metabolism; and 4) these alterations promote insulin 
resistance and delipidation in adipocytes.  Figure 2 provides a possible explanation for in 
vivo studies linking elevated circulating cytokines with insulin resistance (Uysal et al. 
1997, Kern et al. 1995, Moller et al. 2000, Bastard et al. 2000, Kern et al. 2001) and 
hyperlipidemia (Boden et al. 1997).   
 Finally, one could hypothesize from this model that inflammatory pathway 
inhibitors have the potential to antagonize or attenuate insulin resistance and delipidation 
in adipose tissue by inhibiting production of cytokines that activate inflammatory 
pathways and/or attenuating the activation of inflammatory pathways modulating 
adipocyte glucose and lipid metabolism. Indeed, recent studies have demonstrated that 
synthetic (Ruan et al. 2003) and endogenous PPARγ ligands (Straus et al. 2000) can 
attenuate the activation of inflammatory pathways (e.g,, NFκB) in various cell lines.  As 
anti-inflammatory compounds, they have the potential to act as therapeutic agents 
preventing cytokine-induced alterations in adipocyte glucose and lipid metabolism that 
lead to delipidation.   Ruan et al. 2003 reported that troglitazone (TGZ), a member of the 
thiazolidinedione (TZD) class of anti-diabetic compounds and synthetic ligand for the 
PPARγ receptor, inhibits the TNFα-induced and NFκB-mediated downregulation of 
several 3T3-L1 adipocyte genes.  Among those genes inhibited by TGZ are those that 
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prevent the release of fatty acids [(e.g., glycerol-3-phosphate acyltransferase (GPAT) and 
diacylglycerol acyltransferase (DGAT)] and those involved in insulin signaling [(e.g., c-
Cbl associate protein (CAP)].  Using a reporter gene assay in HeLa cells they showed that 
relative luciferase activity for the NFκB promoter was abolished by PPARγ and further 
decreased by TGZ.  This demonstrates that TGZ inhibits p65-dependent transcriptional 
activity of NFκB gene expression. Furthermore, while the data shows TGZ inhibits 
NFκB gene expression, NFκB activation and DNA binding were unaffected in 3T3-L1 
adipocytes according to an ELISA anaylsis of TNFα-induced p65 activity.  Based on 
these data, their conclusion was that TGZ does not inhibit NFκB activity or gene 
expression, but instead functions to block NFκB’s transcriptional downregulation of key 
adipocyte genes regulating glucose and fatty acid uptake.  These molecular events could 
potentially explain the insulin sensitizing effects of TZD’s in adipose tissue. 
 Endogenous PPARγ ligands such as 15d-PGJ2 (a metabolite of Prostaglandin J2) 
can also act in a PPARγ-dependent manner to block the activation of inflammatory 
pathways (e.g., NFκB) thereby preventing the transcription of NFκB target genes (Straus 
et al. 2000). To determine the effects of PPARγ on NFκB activity, experiments were 
designed using PPARγ-negative HeLa cells or HeLa cells transiently cotransfected with 
PPARγ-expression plasmids.  NFκB activity was measured using a reporter gene assay 
coupled to firefly luciferase.  The inhibition of NFκB-activity was significantly reduced 
in HeLa cells transiently expressing PPARγ and the synthetic PPARγ agonist BRL49653 
 
 18
inhibited NFκB activity only in the cells transiently expressing PPARγ.  These data 
suggest PPARγ expression was requisite for the inhibition of NFκB.   
 Collectively, these data provide evidence that synthetic and endogenous PPARγ 
agonists can antagonize cytokine-induced activation of inflammatory signaling pathways.  
By blocking multiple steps in these pathways, PPARγ agonists prevent the 
downregulation of adipocyte genes regulating glucose and fatty acid uptake.  This is one 
of the mechanisms through which PPARγ agonists are believed to protect adipose tissue 
from delipidation and the development of insulin resistance and type 2 diabetes. 
 
Current Knowledge About the Mechanisms by Which CLA Decreases Adiposity 
Once research determined the trans-10, cis-12 CLA isomer was responsible for 
reductions in body fat, studies focused on clarifying the molecular mechanisms 
responsible for CLA’s adipocyte delipidation.  These studies focused primarily on trans-
10, cis-12 CLA’s regulation of adipocyte metabolism by measuring:  1) activity or gene 
expression of enzymes involved in lipid and energy metabolism; and/or 2) activity or 
gene expression of transcription factors regulating adipocyte differentiation and 
maintenance. Evidence from these studies support the concept that trans-10, cis-12 CLA 
modulates the enzymatic activity of steroyl-CoA desaturase-1 (SCD-1) and LPL, thereby 
altering lipid metabolism in differentiating and mature adipocytes.  Trans-10, cis-12 CLA 
decreased the activity of SCD-1 in 3T3-L1 adipocytes, which is thought to reduce the 
availability of monounsaturated substrates for TG synthesis, resulting in decreased TG 
content in adipocytes (Choi et al. 2000).  LPL activity also decreased during trans-10, cis-
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12 CLA treatment, reducing lipid uptake into adipocytes (Park et al. 1997).   Animal 
studies using the trans-10, cis-12 CLA isomer also showed significant reductions in 
activity or gene expression of enzymes involved in lipid and energy metabolism.  Mice 
fed a diet containing 1% CLA (e.g., 50% cis-9, trans-11, 50% trans-10, cis-12 CLA) 
weighed less than controls, due to a decrease in gene expression of FAS and acetyl-CoA 
carboxylase (ACC), two key enzymes regulating lipid synthesis (Tsuboyama-Kasaoka et 
al. 2000).  Mice fed CLA-enriched diets (e.g., 50% cis-9, trans-11, 50% trans-10, cis-12 
CLA) had greater liver mRNA levels for enzymes regulating β-oxidation, which reduced 
TG content in the liver (Takahashi et al. 2003).  Collectively, these data suggest that CLA 
alters the activity or gene expression of key enzymes controlling adipocyte lipid and 
energy metabolism. 
 Initially, PPARα expression was thought to be responsible for many of 
metabolic changes observed in adipocytes following trans-10, cis-12 CLA treatment 
(Moya-Canarena et al. 1999).  Subsequent experiments with PPARα null mice showed  
trans-10, cis-12 CLA could still decrease adiposity, suggesting CLA’s effects were not 
dependent on PPARα activation (Peters et al. 2001).  Work by Granlund et al. (2003) and 
our group (Brown et al. 2003) suggested trans-10, cis-12 CLA’s antiadipogenic effects 
are due instead to decreased PPARγ gene expression and/or activity.  PPARγ promotes 
differentiation and lipid accumulation in adipocytes by forming a heterodimer with RXR 
and binding to PPRE inducing genes responsible for lipid and carbohydrate metabolism. 
   Theoretically any molecule that antagonizes ligand binding to PPARγ or its 
binding to the PPRE of a target gene could downregulate the expression of PPARγ target 
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genes involved in adipocyte metabolism.  In support of this hypothesis, our group found 
that trans-10, cis-12 CLA decreased the expression of PPARγ and its target genes (i.e., 
aP2, GLUT4, perilipin, LPL) in cultures of differentiating human adipocytes (Brown et 
al. 2003) and mature adipocytes (Brown et al. 2004).  Reductions in gene expression 
induced by CLA were preceded by the secretion of the proinflammatory cytokines IL-6 
and IL-8, suggesting they may have some role in mediating the reductions in adipocyte 
TG content (Brown et al. 2004).  A working model presented in Figure 3 by Brown et al. 
(2004) summarizes our proposed molecular mechanisms by which trans-10, cis-12 CLA 
mediates adipocyte delipidation. 
 
Gap in the Knowledge Base 
Recent studies have demonstrated that adipocytes express receptors for the 
proinflammatory cytokines TNFα, IL-6, and IL-8 (Gerhardt et al. 2001, Zhang et al. 
2002, Lagathu et al. 2003).  Treating human and murine adipocytes with IL-6 or TNFα 
alters adipocyte metabolism by stimulating lipolysis and decreasing insulin-stimulated 
glucose uptake, cellular TG content, and/or de novo lipogenesis (Path et al. 2001, Rotter 
et al. 2003, Lagathu et al. 2003).  These cellular effects can be attributed primarily to 
decreased PPARγ adipogenic target genes and PPARγ itself (Rotter et al. 2003, Lagathu 
et al. 2003, Path et al. 2001). 
 Our group demonstrated in cultures of SV cells containing newly
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Figure 3.  CLA-induced hypersecretion of cytokines controls the repression of 
PPARγ target gene expression.  CLA either enters into the adipocyte or the supporting 
stromal vascular (SV) cells, initiating an autocrine/paracrine signaling network. In the SV 
cell, CLA through an unidentified mechanism, increases the mRNA expression and 
secretion of IL-6 and IL-8.  The secreted IL-6 can work in an autocrine manner, binding 
to the SV cell transmembrane IL-6 receptor (IL-6R) activating MEK/ERK or in a 
paracrine manner, binding to the IL-6R in neighboring adipocytes also activating 
MEK/ERK.  Secreted IL-8 only works in a paracrine manner, by binding to its obligate 
receptor (CXCR1) and further amplifying MEK/ERK signaling in the 
adipocyte.  The collective paracrine actions of both IL-6 and IL-8 in the adipocyte result 
in sustained phosphorylation of MEK and ERK and the concomitant translocation of 
ERK into the nucleus.  The ERK-dependent phosphorylation of other transcription factors 
(other TFs) may repress the expression of PPARγ. Collectively, ERK-dependent 
repression of PPARγ gene expression blocks the ability of PPARγ to modulate its 
traditional target genes, resulting in decreased expression of genes involved in 
fatty acid (FA) uptake and metabolism (e.g., aP2, LPL, and GPDH) and glucose uptake 
and metabolism (e.g., GLUT4, CAP, and adiponectin) (taken from Brown et al. 2004). 
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differentiated adipocytes that 30 uM trans-10, cis-12 CLA treatment for 24 h increased 
IL-6 and IL-8 gene expression and protein secretion to a greater extent than controls.  
This increase in cytokine expression and secretion precede a time-dependent 
downregulation of PPARγ2 and its target genes regulating adipocyte differentiation.  The 
changes in human adipocyte metabolism are similar to what is observed following IL-6 
and TNFα treatment, namely reduced glucose uptake and de novo lipogenesis (Path et al. 
2001, Rotter et al. 2003, Lagathu et al. 2003). 
 However, it has yet to be demonstrated the extent to which primary culture of 
human adipose tissue explants, a model more resembling of in situ conditions in human 
adipose tissue, respond similarly to trans-10, cis-12 CLA treatment, vis a vis induce 
proinflammatory synthesis and secretion and downregulate PPARγ2 and its downstream 
target genes. 
Hypothesis and Specific Aims 
Based on the preliminary data from our group presented above, the following central 
hypothesis was formulated:  Human adipose tissue explants treated with trans-10, cis-
12 CLA have increased gene expression and protein secretion of IL-6 and IL-8 and 
decreased gene expression of PPAR-γ2 and its downstream targets compared to 
controls. 
To test this central hypothesis, the following specific aim will be pursued:  Determine the 
extent that trans-10, cis-12 CLA increases IL-6 and IL-8 gene expression and protein 
secretion and decreases PPARγ2 and its downstream target genes in human adipose tissue 
explants. 
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CHAPTER II 
TRANS-10, CIS-12 CONJUGATED LINOLEIC ACID INDUCES INTERLEUKIN 
(IL)-6 AND IL-8 SECRETION AND GENE EXPRESSION IN CULTURES OF 
HUMAN ADIPOSE TISSUE EXPLANTS 
 
 
 
Abstract 
 
 Previously, we reported that primary cultures of human stromal vascular (SV) 
cells containing newly differentiated adipocytes treated with 30 uM trans-10, cis-12 CLA 
for 24 h had greater gene expression and protein secretion of IL-6 and IL-8 than vehicle 
controls (Brown et al. 2004).  In addition, cultures treated with 30 uM trans-10, cis-12 
CLA had decreased mRNA levels of PPARγ2 and several of its downstream target genes.  
However, the effects of trans-10, cis-12 CLA treatment on human adipose tissue explants 
are unknown.  Therefore, we examined the extent to which trans-10, cis-12 CLA 
increased IL-6 and IL-8 gene expression and protein secretion, and decreased mRNA 
levels of PPARγ2 and several of its downstream targets in human subcutaneous adipose 
tissue explants.  Explants (~ 500 mg each) from human subcutaneous adipose tissue were 
treated with either vehicle (BSA) or 30 uM trans-10, cis-12 CLA (CLA) for 8, 24, or 72 
h.  Trans-10, cis-12 CLA treatment increased IL-6 and IL-8 secretion into the media 
(Main effect of treatment: p < 0.05).  Evaluation of the treatment by time interactions 
revealed that cultures treated with trans-10, cis-12 CLA for 72 h had higher (p < 0.05) 
levels of IL-6 and IL-8 in the media compared to the BSA controls.  Similarly, trans-10, 
cis-12 CLA treatment increased the mRNA levels of IL-6 and IL-8 (Main effect of 
 
 24
treatment: p < 0.05).  Evaluation of the treatment by time interactions revealed that 
cultures treated with trans-10, cis-12 CLA had higher (p < 0.05) levels of IL-6 after 24 h 
and higher (p < 0.05) levels of IL-8 after 8 and 24 h of treatment compared to the vehicle 
controls.  However, CLA had no significant effect on the expression of PPARγ or its 
target genes.  These data demonstrate for the first time that trans-10, cis-12 CLA induces 
IL-6 and IL-8 gene expression and protein secretion in cultures of human subcutaneous 
adipose tissue explants. 
 
 25
Introduction 
 CLA refers to a group of naturally occurring isomers of linoleic acid.  
Approximately 4-6 mg/g of CLA is found in ruminant meats and dairy products.  The two 
major CLA isomers occurring in nature are cis-9, trans-11 CLA and trans-10, cis-12 
CLA.  CLA, specifically the trans-10, cis-12 CLA isomer, reduced adiposity in vivo and 
fatty acid incorporation into TG in adipocytes in vitro (Park et al. 1999, Kang et al. 2003, 
Brown et al. 2003, Brown et al. 2004, Granlund et al. 2005).  Trans-10, cis-12 CLA has 
also been shown to decrease mRNA levels for PPARγ2 and several of its adipogenic 
downstream target genes (i.e., GLUT4, aP2, perilipin, LPL, GPDH, and adiponectin), 
thereby decreasing TG accumulation in newly differentiating and promote delipidation of 
mature human adipocytes (Brown et al. 2003, Brown et al. 2004) or 3T3-L1 adipocytes 
(Granlund et al. 2005).  Interestingly, CLA increased mitogen-activated protein kinase 
kinase/extracellular signal-related kinase kinase (MEK/ERK) signaling which was 
essential for CLA’s suppression of the expression of adipogenic target genes and the 
hypersecretion of IL-6 and IL-8 (Brown et al. 2004).  Based on these observations, the 
effect of trans-10, cis-12 CLA treatment on IL-6 and IL-8 gene expression and protein 
secretion in human subcutaneous adipose tissue explants was examined.  Furthermore, 
the extent to which trans-10, cis-12 CLA treatment reduced the mRNA levels of PPARγ2 
and its adipogenic target genes was examined.  In this study, we show that trans-10, cis-
12 CLA-treated explants had greater gene expression and protein secretion of IL-6 and 
IL-8 than vehicle controls.  In addition, trans-10, cis-12 CLA treatment had no significant 
effect on the mRNA levels of PPARγ2 and several of its downstream targets (e.g., 
 
 26
GLUT4, aP2, perilipin, LPL), with the exception of adiponectin, which was decreased 
after 72 h of treatment with CLA compared to controls. 
Materials and Methods 
Chemicals and Reagents 
Trans-10, cis-12 CLA (+ 98% pure) was purchased from Matreya, Inc. (Pleasant Gap, 
PA) and fatty acid free bovine serum albumin (>98%) was purchased from Sigma 
Chemical (St. Louis, MO).  TURBO DNA-free was purchased from Ambion (Austin, 
TX).  Reverse transcription kit and Syber Green real time PCR kit were purchased from 
Qiagen, Inc. (Valencia, CA).  Gene specific primers for quantitative real time PCR (Table 
1) were purchased from Invitrogen, Inc. (Carlsbad, CA) or Integrated DNA 
Technologies, Inc. (Coralville, IA).  ELISA kits for IL-6 (#D6050) and IL-8 (# D8000C) 
were purchased from R & D Systems, Inc. (Minneapolis, MN).  All other chemicals and 
reagents were purchased from Sigma Chemical Co. unless otherwise indicated. 
Fatty Acid Preparation 
Trans-10, cis-12 CLA was complexed to fatty acid-free (>98%) bovine serum albumin 
(BSA) at a 4:1 molar ratio using 1 mM BSA stocks as previously described (Brown et al. 
2004). 
Culture of Human Subcutaneous Adipose Tissue Explants 
Abdominal adipose tissue was obtained from females with a body mass index < 30.0 
during elective surgery with consent from the Institutional Review Board (IRB) at 
University of North Carolina-Greensboro and the Moses Cone and Wesley Long IRB.  
Adipose tissue was weighed out into 500 mg pieces and cut into ~ 5 to 10 mg fragments 
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for explant culture.  Explants were incubated in 5 mL of Dulbecco’s modified Eagle’s 
medium/Ham’s F12 (DMEM/F12 HAM) containing 50 ug/mL gentamicin, 100 U/mL 
penicillin, 100 U/mL streptomycin, 25 mg/mL fungizone, and 1% BSA for approximately 
1 h.  At the conclusion of the incubation period, tissue explants were centrifuged for 30 
sec at 400 x g to remove erythrocytes, then resuspended in the same media without BSA 
for 24 h before treatments were added.  To initiate the experiments, explants were 
transferred to fresh tubes and incubated continuously in serum-free media containing 
either vehicle (BSA) or 30 uM trans-10, cis-12 CLA for 0, 8, 24, or 72 h.  At the 
conclusion of each time point, tissue explants were frozen in liquid nitrogen and stored at 
-80 °C for RNA isolation and conditioned media was harvested and frozen at –80 °C for 
ELISA. 
RNA Isolation and Quantitative Real Time PCR Analysis 
Tissue explants were pulverized in liquid nitrogen prior to homogenization in 
guanidinium thiocyantate solution.  Following homogenization, surface lipids were 
removed to ensure better RNA quality. Total RNA was isolated using the single-step 
method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction 
(Chomczynski et al. 1987).  DNA was removed from RNA preparations using TURBO 
DNA-free, and the first strand synthesis was performed using oligo dT15 primers and 
Omniscript RT kit (Qiagen). 
 Real time quantitative PCR was performed in a Smartcycler (Cepheid, Sunnyvale, 
CA) using QuantiTect SYBR Green PCR Kit (Qiagen) for 40 cycles.  Gene-specific 
primer pairs used for real time quantitative PCR are shown in Table 1.  To account for 
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variation related to cDNA input or the presence of PCR inhibitors, the endogenous 
reference gene hOS-9 (Weisberg et al. 2003) was simultaneously quantified in a separate 
tube for each sample.  A melting curve was also generated for every PCR product to 
check the specificity of the PCR.  Following melting curve analyses, standard curves for 
each target gene were constructed using serial dilutions of a reference cDNA sample.  
Relative mRNA quantification of target genes with comparable amplification efficiencies 
to the endogenous reference gene was determined using the ∆∆Ct method.  Relative 
mRNA quantification of target genes with amplification efficiencies different from the 
endogenous reference gene was determined using “Guidelines for relative quantification 
with different amplification efficiencies” (from “Critical Factors for Successful Real-
Time PCR” –www.qiagen.com). 
Immunoassay 
Aliquots of conditioned media were measured for immunodetectable IL-6 and IL-8 using 
a sandwich immunoassay from R & D Systems, Inc.  Both immunoassays used an 
antihuman monoclonal antibody for capture and a rabbit antihuman antibody for 
detection.  Samples of conditioned media were diluted 1:20-1:100 for IL-6 and 1:30-1:80 
for IL-8.  IL-6 and IL-8 concentrations (pg/g of tissue) were determined based on the 
standard curve of the assay. 
Statistical Analyses 
Data are expressed as the mean + S.E.  Data were analyzed using two-way analysis of 
variance (Main Effects: Time (n=3) and Treatment (n=2), followed by Student’s t-tests 
for multiple comparisons of the time by treatment interactions.  Differences were 
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Table 1.  Primer sequences for quantitative real-time PCR 
 
Target 
Gene 
 Primer Sequence Accession 
Number 
Adiponectin Sense 
Antisense 
5’-GCAGAGATGGCACCCCTG–3’ 
5’-GGTTTCACCGATGTCTCCCT–3’ 
NM_ 
004797 
aP2 Sense 
Antisense 
5’-ATATGAAAGAAGTAGGAGTGGGCTTT–3’ 
5’-CCATGCCAGCCACTTTCC–3’ 
NM- 
001442 
GLUT4 Sense 
Antisense 
5’-GCTACCTCTACATCATCCAGAATCTC-3’ 
5’-CCAGAAACATCGGCCCA–3’ 
NM__0010
42 
00584 
hOS-9 Sense 
Antisense 
5’-TAAACGCTACCACAGCCAGACC–3’ 
5’-AGCCGAGGAGTGCGAATG–3’ 
NM_ 
006812 
IL-6 Sense 
Antisense 
5’-AAATGCCAGCCTGCTGACGAA–3’ 
5’-AACAACAATCTGAGGTGCCCATGCTAC-3’ 
NM_ 
000600 
IL-8 Sense 
Antisense 
5’-GAATGGGTTTGCTAGAATGTGATA–3’ 
5’-CAGACTAGGGTTGCCAGATTTAAC–3’ 
NM_ 
00584 
PPARγ Sense 
Antisense 
5’-AGCAAACCCCTATTCCATGCTA–3’ 
5’-ATCAGTGAAGGAATCGCTTTCTG–3’ 
NM_ 
005037 
TNFα Sense  
Antisense 
5’-TCTTCTCGAACCCCGAGTGA–3’ 
5’-CCTCTGATGGCACCACCAG–3’ 
NM_ 
000594 
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considered significant if p<0.05.  All analyses were performed using JMP IN v4.04 (SAS 
Institute, Cary, NC) software. 
Results 
Trans-10, cis-12 CLA increases IL-6 and IL-8 protein secretion from human adipose  
tissue explants 
To determine the extent to which trans-10, cis-12 CLA increased the amount of IL-6 and 
IL-8 secreted from human adipose tissue explants, explants were incubated for 8, 24, or 
72 h with 30 uM trans-10, cis-12 CLA or BSA vehicle.  Conditioned media was collected 
at each time point and IL-6 and IL-8 concentrations were measured using ELISA.  CLA 
treatment increased IL-6 and IL-8 secretion into the media (Main effect of treatment: p < 
0.05).  As shown in Figures 4 and 5, trans-10, cis-12 CLA treatment for 72 h increased 
IL-6 and IL-8 levels in the media compared to BSA vehicle.   
Trans-10, cis-12 CLA increases gene expression of IL-6 and IL-8 
To determine the extent to which CLA-mediated secretion of IL-6 and IL-8 in human 
adipose tissue explants was the result of increased gene expression, explants were treated 
with 30 uM trans-10, cis-12 CLA or BSA vehicle for 8, 24, or 72 h.  CLA treatment 
increased IL-6 and IL-8 mRNA levels (Main effect of treatment: p < 0.05).  Messenger 
RNA levels for IL-6 (Fig. 6) were higher at 24 h in trans-10, cis-12 CLA-treated explants 
compared to the vehicle controls.  Explants treated with CLA had higher IL-8 mRNA 
levels at 8 and 24 h when compared to BSA controls (Fig. 7). 
The effects of trans-10, cis-12 CLA on PPARγ2 and several of its downstream target 
genes 
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To determine the effect of trans-10, cis-12 CLA on PPARγ2 and PPARγ2 target genes in 
human adipose tissue, explants were treated with 30 uM trans-10, cis-12 CLA or BSA 
vehicle continuously for 8, 24, or 72 h.  As shown in Figure 8, trans-10, cis-12 CLA had 
no significant effect on PPARγ2 mRNA levels at each time interval compared to vehicle.  
In addition, cultures treated with 30 uM trans-10, cis-12 CLA had similar levels of 
mRNA for GLUT4 (Fig. 9) and aP2 (Fig. 10) when compared to BSA controls.  
However, explants treated with 30 uM trans-10, cis-12 CLA for 72 h had higher 
adiponectin mRNA levels compared to BSA controls (Fig. 11).   
Discussion  
These data are the first to show that trans-10, cis-12 CLA increases the gene expression 
and protein secretion of IL-6 and IL-8 in cultures of human adipose tissue explants.  
Similar to cultures of SV cells containing newly differentiated adipocytes, we propose in 
our working model that trans-10, cis-12 CLA increases cytokine gene expression and 
secretion in human subcutaneous adipose tissue through the following mechanism(s):  1) 
CLA activates a membrane protein or enters the SV cells in adipose tissue by simple 
diffusion and is converted to a metabolite; and 2) the membrane protein or CLA 
metabolite activates a signal activating NFκB and ERK ½, inducing the synthesis of the 
cytokines such as IL-6 and IL-8, predominantly from the SV cells. 
 This working model is supported by the following preliminary data from our 
research group (Chung et al. 2005 submitted to J. Biol. Chem.):  1) the non-differentiated 
SV cells produced 10-fold and 7-fold more IL-6 and IL-8, respectively, in response to 24 
h treatment with CLA than did differentiated cultures of adipocytes treated with CLA 2)
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Figure 4.  Trans-10, cis-12 CLA increases IL-6 secretion.  Human adipose tissue 
explants were incubated continuously for 8, 24, or 72 h with 30 uM trans-10, cis-12 CLA 
(CLA) or BSA vehicle (BSA).  At each time point, conditioned media was collected for 
IL-6 determination using an ELISA.  IL-6 concentrations are expressed as a percentage of 
8 h BSA vehicle.  Means (+ S.E.; n = 5-8) for IL-6 measurements were obtained from 
three independent experiments from different human subjects.  Means not sharing a 
common superscript differ, p < 0.05. 
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Figure 5.  Trans-10, cis-12 CLA increases IL-8 secretion.  Human adipose tissue 
explants were incubated continuously for 8, 24, or 72 h with 30 uM trans-10, cis-12 CLA 
(CLA) or BSA vehicle (BSA).  At each time point, conditioned media was collected for 
IL-8 determination using an ELISA.  IL-8 concentrations are expressed as a percentage of 
8 h BSA vehicle.  Means (+ S.E.; n = 5-8) for IL-8 measurements were obtained from 
three independent experiments from different human subjects.  Means not sharing a 
common superscript differ, p < 0.05. 
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Figure 6.  Trans-10, cis-12 CLA-induced alterations in IL-6 gene expression.  Human 
adipose tissue explants were incubated with 30 uM trans-10, cis-12 CLA (CLA) or BSA 
vehicle (BSA) for 8, 24, or 72 h.  Explants were frozen in liquid nitrogen at each time 
interval and RNA was harvested for first strand cDNA synthesis.  Real time quantitative 
PCR analyses were performed to determine IL-6 expression relative to 8 h BSA vehicle 
control.  The internal control gene amplified in osteosarcoma (hOS-9) was used to 
normalize the expression data.  Means (+ S.E.; n = 2-4) for IL-6 expression were 
obtained from one human subject.  Means not sharing a common superscript differ, p < 
0.05. 
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Figure 7.  Trans-10, cis-12 CLA-induced alterations in IL-8 gene expression.  Human 
adipose tissue explants were incubated with 30 uM trans-10, cis-12 CLA (CLA) or BSA 
vehicle (BSA) for 8, 24, or 72 h.  Explants were frozen in liquid nitrogen at each time 
interval and RNA was harvested for first strand cDNA synthesis.  Real time quantitative 
PCR analyses were performed to determine IL-8 expression relative to 8 h BSA vehicle 
control. The internal control gene amplified in osteosarcoma (hOS-9) was used to 
normalize the expression data.  Means (+ S.E.; n = 2-4) for IL-8 expression were 
obtained from one human subject.  Means not sharing a common superscript differ, p < 
0.05. 
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Figure 8.  Trans-10, cis-12 CLA-induced alterations in PPAR gamma gene 
expression.  Human adipose tissue explants were incubated with 30 uM trans-10, cis-12 
CLA (CLA) or BSA vehicle (BSA) for 8, 24, or 72 h.  Explants were frozen in liquid 
nitrogen at each time interval and RNA was harvested for first strand cDNA synthesis.  
Real time quantitative PCR analyses were performed to determine PPAR gamma 
expression relative to 8 h BSA vehicle control.  The internal control gene amplified in 
osteosarcoma (hOS-9) was used to normalize the expression data.  Means (+ S.E.; n = 2-
4) for PPAR gamma expression were obtained from one human subject.  Means not 
sharing a common superscript differ, p < 0.05. 
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Figure 9.  Trans-10, cis-12 CLA-induced alterations in GLUT4 gene expression.  
Human adipose tissue explants were incubated with 30 uM trans-10, cis-12 CLA 
(CLA)or BSA vehicle (BSA) for 8, 24, or 72 h.  Explants were frozen in liquid nitrogen 
at each time interval and RNA was harvested for first strand cDNA synthesis.  Real time 
quantitative PCR analyses were performed to determine GLUT4 expression relative to  
8 h BSA vehicle control.  The internal control gene amplified in osteosarcoma (hOS-9) 
was used to normalize the expression data.  Means (+ S.E.; n = 2-4) for GLUT4 
expression were obtained from one human subject.  Means not sharing a common 
superscript differ, p < 0.05. 
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Figure 10.  Trans-10, cis-12 CLA-induced alterations in aP2 gene expression.  
Human adipose tissue explants were incubated with 30 uM trans-10, cis-12 CLA (CLA) 
or BSA vehicle (BSA) for 8, 24, or 72 h.  Explants were frozen in liquid nitrogen at each 
time interval and RNA was harvested for first strand cDNA synthesis.  Real time 
quantitative PCR analyses were performed to determine aP2 expression relative to 8 h 
BSA vehicle control.  The internal control gene amplified in osteosarcoma (hOS-9) was 
used to normalize the expression data.  Means (+ S.E.; n = 2-4) for aP2 expression were 
obtained from one human subject.  Means not sharing a common superscript differ, p < 
0.05. 
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Figure 11.  Trans-10, cis-12 CLA-induced alterations in adiponectin gene 
expression.  Human adipose tissue explants were incubated with 30 uM trans-10, cis-12 
CLA (CLA) or BSA vehicle (BSA) for 8, 24, or 72 h.  Explants were frozen in liquid 
nitrogen at each time interval and RNA was harvested for first strand cDNA synthesis.  
Real time quantitative PCR analyses were performed to determine adiponectin expression 
relative to 8 h BSA vehicle control.  The internal control gene amplified in osteosarcoma 
(hOS-9) was used to normalize the expression data.  Means (+ S.E.; n = 2-4) for 
adiponectin expression were obtained from one human subject.  Means not sharing a 
common superscript differ, p < 0.05.
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cytokine secretion in differentiated cultures of adipocytes treated with CLA was preceded 
by IκBα degradation, IKK phosphorylation, and increased p50 and p65 translocation to 
the nucleus indicating NFκB activation; 3) NFκB p50 and p65 DNA binding in CLA-
treated cultures of differentiated adipocytes was increased by approximately 120% and 
80%, respectively, when compared to BSA control; and 4) NFκB selective inhibitors 
block the acute induction of IL-6 gene expression in CLA-treated differentiated 
adipocytes.  In further support of our model, Harkins et al. 2003 demonstrated that LPS-
stimulated SV cells from adipose tissue of obese mice had higher levels of secreted IL-6 
than adipocytes.  In addition, LPS-stimulated SV cells from adipose tissue of obese mice 
had greater levels of IL-6 mRNA than adipocytes.  Similarly, the non-adipocyte fraction 
isolated from human subcutaneous and visceral adipose tissue accounted for 96% and 
92% of secreted IL-6 and IL-8, respectively (Fain et al. 2003).  Finally, Chen et al. (1999) 
demonstrated that IL-6 and IL-8 possess a nuclear factor κB response element (κBRE).  
Collectively, these data support our working model explaining the mechanisms and 
source of CLA’s proinflammatory response (i.e., increased secretion and mRNA levels of 
IL-6) in human subcutaneous adipose tissue. Additionally, it should be mentioned that 
LPS treatment (10 ug/mL) increased the secretion and gene expression of IL-6 and IL-8 
(data not shown) in human subcutaneous adipose tissue explants, demonstrating the 
responsiveness of these explants to immunomodulatory effectors. 
 Our hypothesis was that trans-10, cis-12 CLA would decrease the mRNA 
expression of PPARγ2 and PPARγ2 adipogenic targets (i.e., GLUT4, adiponectin, and 
aP2).  However, treatment with 30 uM trans-10, cis-12 CLA treatment only decreased 
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adiponectin mRNA levels after 72 h compared to controls.  While a 30 uM concentration 
is sufficient to exert anti-adipogenic effects (i.e., decreased gene expression of PPARγ2 
and its downstream adipogenic genes) in newly differentiated human adipocytes treated 
for up to 9 d (Brown et al. 2004), a higher concentration might be needed to deliver a 
comparable amount of CLA to the cells in the interior of human adipose tissue explants.  
Brown et al. 2004 reported the greatest decrease in mRNA levels of PPARγ2 and 
PPARγ2 downstream targets in cultures treated with CLA for 9 d.  This also suggests a 
longer CLA treatment might be required to decrease mRNA levels of adipogenic genes.  
Fried et al. 1998 have demonstrated adipose tissue explants cultured for up to 7 d are still 
responsive to hormones such as insulin and are still capable of secreting IL-6.  Evidence 
from studies with murine 3T3-L1 adipocytes and mature human adipocytes support the 
concept that trans-10, cis-12 CLA is a modulator of PPARγ2, the master regulator of 
adipocyte differentiation.  In these studies, trans-10, cis-12 CLA treatment decreased the 
gene expression of PPARγ2 and its adipogenic downstream targets in murine and human 
preadipocytes (Kang et al. 2003, Brown et al. 2003) and mature adipocytes (Granlund et 
al. 2003, Brown et al. 2004).  Synthetic PPARγ antagonists exert similar effects such as: 
1) downregulation of PPARγ2 and its target genes regulating adipogenesis; 2) reduced 
conversion of preadipocytes to adipocytes; and 3) increased adipocyte delipidation to 
those observed in trans-10, cis-12 CLA-treated cultures.  These outcomes strengthen the 
argument that CLA’s antiadipogenic effects depend largely on PPARγ2 modulation 
(Rieusset et al. 2002, Mukherjee et al. 2000).  However, future research is needed to 
determine whether trans-10, cis-12 CLA decreases mRNA levels of PPARγ2 and its 
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downstream adipogenic targets in human adipose tissue explants and whether these 
decreases are associated with the secretion of the proinflammatory cytokines IL-6 and IL-
8. 
 In summary, our data with human adipose tissue explants demonstrates that 
trans-10, cis-12 CLA increases the gene expression and secretion of IL-6 and IL-8 in 
cultures of human adipose explants.  These data support previous data from our research 
group showing that trans-10, cis-12 CLA increases IL-6 and IL-8 secretion and gene 
expression in cultures of differentiated adipocytes.
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CHAPTER III 
EPILOGUE 
 
 
 
Here we demonstrated for the first time that trans-10, cis-12 CLA increased the gene 
expression and secretion of the proinflammatory cytokines IL-6 and IL-8 in human 
adipose tissue explants.  We also hypothesized that trans-10, cis-12 CLA would decrease 
the expression of PPARγ2 and its downstream adipogenic genes (e.g., GLUT4, 
adiponectin, and aP2), although these data were inconclusive.  If time and resources were 
not limiting, the following experiments could be conducted to further support these 
findings and determine the degree to which CLA exerts anti-adipogenic effects in human 
adipose tissue explants. 
 In our experiment to determine CLA’s anti-adipogenic effects on human 
subcutaneous adipose tissue explants, the concentration of trans-10, cis-12 CLA used was 
30 uM.  At this concentration, only one significant difference was obtained between 
explants treated with CLA or BSA for mRNA levels of adipogenic genes (i.e., PPARγ2, 
GLUT4, adiponectin, and aP2).  Adiponectin mRNA for explants treated with CLA was 
decreased at 72 h compared to BSA vehicle.  Interestingly, of the adipogenic genes 
measured in our experiment, Brown et al. 2004 reported that CLA treatment decreased 
adiponectin mRNA by 100% at 72 h in cultures of newly differentiated adipocytes.  
While a 30 uM concentration is sufficient to exert anti-adipogenic effects (i.e., decreased 
gene expression of PPARγ2 and its downstream adipogenic genes) in newly  
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differentiated human adipocytes treated for up to 9 d (Brown et al. 2004), a higher 
concentration might be needed to deliver a comparable amount of CLA to the cells in 
human adipose tissue.  In addition, Brown et al. 2004 reported the greatest decrease in 
mRNA levels of PPARγ2 and PPARγ2 downstream targets in cultures treated with CLA 
for 9 d.  This suggests a longer treatment could be required to observe a significant 
decrease in the mRNA levels of adipogenic genes.  Therefore, my first experiment would 
be a dose response/time course study that would allow me to investigate the anti-
adipogenic effects of CLA when manipulating these variables.  The concentrations of 
CLA used would still need to be physiologically relevant, so 30 uM and 60 uM could be 
used.  In addition, adipose tissue explants could be cultured up to 7 d because Fried et al. 
1998 have demonstrated adipose tissue explants cultured for this length are still viable 
and secrete IL-6.  Real time PCR would then be used to determine if CLA decreases the 
mRNA levels of PPARγ2, GLUT4, adiponectin, and aP2, which are genes involved in 
regulating adipogenesis.  If a decrease in mRNA is demonstrated, follow up experiments 
could be conducted to determine if the protein levels of PPAR PPARγ2, GLUT4, 
adiponectin, and aP2 have decreased similar to mRNA levels.  Homogenization and 
protein determination could be carried out using the method outlined by Lappas et al. 
2003.  Following protein determination, immunoblotting would be used to determine 
CLA’s effect on the level of each protein. 
 Here we demonstrated that treatment with trans-10, cis-12 CLA induces the 
expression of IL-6 and IL-8 mRNA in adipose tissue explants.  Preliminary data from our 
group has demonstrated that NFκB activation is requisite for CLA’s induction of IL-6 
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gene expression in differentiated cultures of adipocytes at 3 h (Chung et al. 2005).  Based 
on these data, a second experiment could be conducted to determine whether CLA 
induces the protein expression of NFκB and other transcription factors known to induce 
IL-6 gene expression (e.g., NF-IL6 and AP-1).  If the expression of one or more of these 
transcription factors is induced by CLA, then protein expression of putative upstream 
kinases [e.g., ERK 1/2 and protein kinase C (PKC)] could also be assessed.  Following 
protein determination, immunoblotting would be used to determine CLA’s effect on the 
level of each protein. 
 If a CLA-mediated increase in protein expression could be demonstrated for 
NFκB, it would be interesting to determine the impact of NFκ inhibitors on CLA-induced 
IL-6 and IL-8 gene expression and protein secretion in adipose tissue explants.  A third 
experiment could be designed to pre-treat adipose tissue explants with either PSI or 
Bay11-7082 (Lappas et al. 2004) that block different steps in the process of NFκB 
activation.  PSI blocks the degradation of polyubiquitinated IκBα in the proteosome and 
Bay11-7082 inhibits the phosphorylation of IκBα by IκBα kinase.  After pretreating the 
explants could be treated with CLA or vehicle to study the effect of each of these 
inhibitors on IL-6 gene expression and protein secretion.  Bacterial lipopolysaccharide 
(LPS), which has been shown to induce NFκB activity (Lappas et al. 2004), could be 
used as a positive control for the experiment.  IL-6 secreted into the media would be 
harvested and measured using ELISA and IL-6 gene expression in the explants would be 
measured using Real time quantitative PCR. 
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 Finally, based on recent evidence from our research group and others, we 
propose that CLA increases cytokine (i.e., IL-6 and IL-8) secretion primarily in the non-
adipocyte (i.e., SV cell) population in human subcutaneous adipose tissue explants and 
newly differentiated adipocytes (Brown et al. 2004).  This hypothesis is supported by the 
following evidence: 1) Weisberg et al. 2003 and Xu et al. 2003 reported that the SV cells 
in the adipose tissue of mice had greater mRNA levels of the cytokines TNFα and IL-6; 
2) Fain et al. 2004 reported that greater than the non-adipocyte population in human 
adipose tissue explants accounted for 93% of IL-6 secreted; and 3) Harkins et al. 2004 
demonstrated that 3T3-L1 preadipocytes had significantly higher IL-6 mRNA and IL-6 
secretion than differentiated 3T3-L1 adipocytes.  To test this hypothesis, two different 
experimental designs could be used.  The first design would use a buoyant density 
gradient to isolate differentiated adipocytes from SV cells grown in cell culture.  The 
second design previously used by Fain et al. 2003 and Weisberg et al. 2003 would isolate 
adipocytes from SV cells by low-speed centrifugation (400 – 1000 x g) following 
collagenase digestion of adipose tissue. 
 Following CLA treatment, the first design requires that cultures of SV cells 
containing differentiated adipocytes be detached from the cell culture monolayer.  To 
minimize cell lysis, a chelating agent or a microbial-derived trypsin could be used to lift 
the cells from the monolayer.  To prevent handling of the adipocytes and remove excess 
gradient media from the tube, the bottom of the tube could be punctured and drained.  SV 
cells would then be harvested and pelleted for RNA isolation using a guanidinium 
isothiocyanate (GTC) solution.  After harvesting the SV cells and removing the gradient 
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media, the floating adipocytes would be lysed in GTC solution.  The samples would then 
be analyzed for mRNA expression of cytokines (i.e., IL-6 and IL-8), adipocyte markers 
(aP2 and leptin) (Fain et al. 2003, Abderrahim-Ferkoune et al. 2004) and preadipocyte 
markers [(preadipocyte factor-1 (Pref-1) and Aortic carboxypeptidase-like 
protein(ACLP)] (Abderrahim-Ferkoune et al. 2004) using Real time PCR. 
 The second design would require adding human adipose tissue minced into 
small (~ 10 mg) fragments to a suspension containing bacterial collagenase 
(approximately 0.03 mg/mL) and Dulbecco’s modified Eagle’s medium/Ham’s F12.  The 
tissue is then digested in a rotary water bath shaker for approximately 1 to 2 h.  The 
digested suspension is filtered through 200 to 250-um mesh fabric into a centrifuge tube 
and then spun at approximately 400-1000 x g for 1 min.  Following centrifugation, the 
SV cells will form a pellet while the adipocytes remain in suspension.  The medium and 
SV cells are removed from the tube and then fresh medium containing either 30 uM 
trans-10, cis-12 CLA or BSA vehicle is added to each cell fraction.  IL-6 secreted into the 
media by each cell fraction would be harvested and measured using ELISA.  Then the SV 
cells and adipocytes would be analyzed for mRNA expression of cytokines , adipocyte 
markers, and preadipocyte markers using Real time quantitative PCR.  To normalize the 
cytokine ELISA data, the cytokine concentration (pg/mL) would be divided by the wet 
weight of adipose tissue before digestion.  This is the method used by Fain et al. 2003 to 
normalize cytokine ELISA data from each cell fraction following tissue digestion. 
 In conclusion, the experiments discussed in this section would further validate 
our data demonstrating for the first time that trans-10, cis-12 CLA stimulates cytokine 
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secretion and induces cytokine gene expression in adipose tissue explants.  In addition, 
they would also examine the effect of CLA on the following parameters: 1) adipogenic 
protein and gene expression; 2) protein expression of transcription factors and kinases 
(i.e., NFκB, NF-IL-6, AP-1, ERK, PKC) leading to cytokine secretion and gene 
expression; and 3) the induction of cytokine gene expression in the SV cell and adipocyte 
fraction isolated from human adipose tissue as well as the cytokine secretion from each 
cell population.  Collectively, these experiments would help address the following 
research questions related to CLA’s effects on human adipose tissue explants: 1) how 
CLA works mechanistically to induce a pro-inflammatory response (i.e., increased 
cytokine secretion and gene expression); 2) the predominant cellular source (i.e. SV cells 
vs. adipocytes) of the CLA-mediated response; and 3) whether or not CLA treatment 
exerts anti-adipogenic effects.
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